Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

40.12 -1.32 (-3.19%)
Streaming Delayed Price Updated: 9:39 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 Next >
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%. 
Via Benzinga
Qiagen Earnings Review: Q4 Summary
Via Benzinga
Qiagen: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
Via ACCESS Newswire
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
From QIAGEN N.V.
Via Business Wire
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
From QIAGEN N.V.
Via Business Wire
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Via The Motley Fool
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
From QIAGEN N.V.
Via Business Wire
QIAGEN delivers solid Q4 2024 growth ahead of outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
From QIAGEN N.V.
Via Business Wire
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
From QIAGEN N.V.
Via Business Wire
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
From QIAGEN N.V.
Via Business Wire
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
From QIAGEN N.V.
Via Business Wire
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. 
Via MarketBeat
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.